CDT Equity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on August 4 and August 5, 2025, for CDT Equity Inc. (formerly Conduit Pharmaceuticals Inc.). The filing details a corporate name change, the appointment of a permanent Chief Financial Officer, and the results of the 2025 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and structural changes rather than financial performance metrics.
Material Changes and Corporate Actions
- Corporate Name Change: Effective August 5, 2025, the company changed its name from "Conduit Pharmaceuticals Inc." to "CDT Equity Inc." The ticker symbol "CDT" and CUSIP number remain unchanged.
- Executive Appointment: James Bligh, previously the Interim Chief Financial Officer and a co-founder, was appointed as the permanent Chief Financial Officer effective August 4, 2025. His compensation remains consistent with prior disclosures.
- Stock Incentive Plan Amendment: Stockholders approved an amendment to the 2023 Stock Incentive Plan, authorizing an additional 2,000,000 shares for awards.
Stockholder Voting Results
At the Annual Meeting held on August 5, 2025, stockholders representing over one-third of outstanding shares voted on three proposals:
- Proposal 1 (Election of Directors): All five nominees (Andrew Regan, Freda Lewis-Hall, James Bligh, Chele Chiavacci Farley, and Simon Fry) were elected. Votes ranged from approximately 625,000 to 640,000 "For" each director.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of CBIZ CPAs P.C. as the independent registered public accounting firm for the year ending December 31, 2025. Votes: 1,140,640 For, 68,569 Against.
- Proposal 3 (Stock Incentive Plan): Stockholders approved the amendment to increase the authorized share reserve. Votes: 592,230 For, 61,466 Against.
Outlook, Risks, and Contingencies
The filing includes standard forward-looking statements regarding the name change and its potential impacts, noting that actual results may differ due to risks and uncertainties. No specific new risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the effective date of the name change (August 5, 2025) and confirm ticker symbol continuity on Nasdaq.
- Review the full text of the Amended and Restated 2023 Stock Incentive Plan (Exhibit 10.1) for specific award terms.
- Confirm the background and prior transaction experience of the new permanent CFO, James Bligh.
- Check subsequent filings for the first financial report under the new corporate name.